A5007987857- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Salivary Gland Tumors Diagnosis and Treatment
- Renal cell carcinoma treatment
- Tracheal and airway disorders
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neuroendocrine Tumor Research Advances
- Colorectal Cancer Treatments and Studies
- Renin-Angiotensin System Studies
- Radiomics and Machine Learning in Medical Imaging
- Esophageal Cancer Research and Treatment
- Medical Imaging and Pathology Studies
- Prostate Cancer Diagnosis and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Cancer Mechanisms and Therapy
- Pericarditis and Cardiac Tamponade
- Hormonal Regulation and Hypertension
- HER2/EGFR in Cancer Research
The Maria Sklodowska-Curie National Research Institute of Oncology
2012-2024
Foundation for Polish Science
2024
Centrum Onkologii
2012-2021
National Institute of Oncology
2021
National Academy of Medicine
2011-2012
Wojskowy Instytut Medycyny Lotniczej
2012
Medical University of Warsaw
2012
<i>Background/Aims:</i> This retrospective analysis compared progression-free survival (PFS) in 111 patients who developed or had preexisting hypertension with those did not during treatment second-line sunitinib. Secondary objectives included overall (OS) and safety. <i>Methods:</i> Patients metastatic renal cell carcinoma (mRCC) received sunitinib 50 mg orally once daily 6-week cycles according to a 4-week on/2-week off schedule. Treatment was continued until...
Molecular testing is recommended in patients with metastatic non-small cell lung cancer (NSCLC), but the extent of its use Poland unknown. The aim POL-MOL study was to investigate frequency using molecular Polish NSCLC. invited oncologists completed two questionnaires, and data for 1001 undergoing systemic treatment NSCLC were collected. tests following genetic mutations recorded:
Savolitinib is a highly selective MET tyrosine kinase inhibitor. involved in numerous cellular processes such as proliferation, differentiation and the formation of distant metastases. amplification overexpression are quite common many cancers, but exon 14 skipping alteration most non-small cell lung cancer (NSCLC). The role signaling bypass pathway development acquired resistance to inhibitor (TKI) epidermal growth factor receptor (EGFR) therapy patients with EGFR gene mutation was...
The study was conducted in the era when maintenance immunotherapy with durvalumab not available clinical practice after chemoradiotherapy (CRT) unresectable non-small-cell lung cancer (NSCLC). main aim of to check whether presence cardiovascular diseases (CVD) and their pharmacotherapy affects overall survival (OS) such NSCLC patients undergoing sequential CRT. group 196 were analyzed: 101 CVD (51.53%) 95 other reasons qualification for CRT (decreased performance status, older age,...
The purpose of the present study was to determine relationship between iatrogenic arterial hypertension or baseline cardiovascular comorbidities and outcomes in metastatic renal cell cancer (mRCC) patients treated with sorafenib.The included 148 mRCC sorafenib, 63 (43%) had preexisting hypertension, 18 (12%) coronary artery disease, 15 (10%) mild heart failure. Resting blood pressure (BP) monitored by clinic home measurements. Sorafenib-induced defined as systolic BP ≥140 and/or diastolic...
The efficacy of nivolumab and atezolizumab in advanced pre-treated NSCLC was documented prospective trials. We aim to confirm the benefits indicate predictive factors for immunotherapy daily practice. This study a retrospective analysis. median PFS OS were estimated using Kaplan-Meier method. log-rank test used comparisons. Multivariate analyses performed Cox regression A total 260 patients (ECOG 0-1) with (CS III-IV) eligible receive or as second-line treatment. Median three months (95%...
Concurrent chemoradiotherapy is recommended for locally advanced and unresectable non-small-cell lung cancer (NSCLC), but radiotherapy alone may be used in patients that are ineligible combined-modality therapy due to poor performance status or comorbidities, which concern elderly particular. The best candidates sequential remain undefined. purpose of the study was determine importance a patients’ age during qualification chemoradiotherapy. enrolled 196 patients. Older (age > 65years)...
Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant is chemotherapy, after which only receive symptomatic treatment. The available results of phase II trials sorafenib in hormone-refractory indicate that, despite relatively short progression-free survival, may be associated good outcomes terms overall survival and maintenance quality life. study presents authors' critical opinions observations...
The role of sequential chemoradiotherapy in non-small cell lung cancer (NSCLC) patients who are not eligible for concurrent therapy has been clearly defined. aim this study was to determine the usefulness Karnofsky performance status (KPS) monitoring and define factors determining clinical deterioration during treated from July 2009 October 2014. included 196 patients. stage defined as III A 94 (48%) B 102 (52%). Reduced KPS found 129 (65.8%). Baseline had no significant prognostic...
Castrate-resistant prostate cancer represents a significant clinical challenge.Currently, the standard treatment for patients with castrate-resistant is chemotherapy, after which only receive symptomatic treatment.The available results of phase II trials sorafenib in hormone-refractory indicate that, despite relatively short progression-free survival, may be associated good outcomes terms overall survival and maintenance quality life.The study presents authors' critical opinions observations...
Venous thromboembolic events (VTE) are often diagnosed in ALK-positive lung cancer although it has not been demonstrated how their co-occurrence affects patients' survival.
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Piórek A, Tabor S, Jaśkiewicz P, et al. A case of adenoid cystic carcinoma trachea: treatment complications and radiotherapy role. Journal Contemporary Brachytherapy. 2021. doi:10.5114/jcb.2021.109853. APA Piórek, A., Tabor, S., Jaśkiewicz, P., Kasprowicz, Zaborowska-Szmit, M., & Winiarczyk, K. (2021). https://doi.org/10.5114/jcb.2021.109853 Chicago Aleksandra, Sylwia Piotr Anetta Magdalena Kinga Adam Płużański...
Advanced non-small-cell lung cancer is still a challenging disease. Chemotherapy and EGFR or ALK tyrosine kinase inhibitors are well-established options. Immunotherapy with immune-checkpoint significantly improves survival both in first- second-line treatment. Atezolizumab one of the novel immunotherapies. This paper presents current data on mechanisms action clinical atezolizumab treatment patients advanced cancer.